Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 4/2012

01-04-2012 | Research Articles

Lack of T-cell responses following autologous tumour lysate pulsed dendritic cell vaccination, in patients with relapsed osteosarcoma

Authors: Nourredine Himoudi, Rebecca Wallace, Kathryn L. Parsley, Kimberly Gilmour, Alpha-Umaru Barrie, Karen Howe, Rong Dong, Neil J. Sebire, Antony Michalski, Adrian J. Thrasher, John Anderson

Published in: Clinical and Translational Oncology | Issue 4/2012

Login to get access
Metadata
Title
Lack of T-cell responses following autologous tumour lysate pulsed dendritic cell vaccination, in patients with relapsed osteosarcoma
Authors
Nourredine Himoudi
Rebecca Wallace
Kathryn L. Parsley
Kimberly Gilmour
Alpha-Umaru Barrie
Karen Howe
Rong Dong
Neil J. Sebire
Antony Michalski
Adrian J. Thrasher
John Anderson
Publication date
01-04-2012
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 4/2012
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-012-0795-1

Other articles of this Issue 4/2012

Clinical and Translational Oncology 4/2012 Go to the issue

Correspondence

Prophylactic cranial irradiation: the state of the art and areas of uncertainty

Research Articles

Correlation between surgical modality and clinicopathologic characteristics for ureteral transitional cell carcinoma

Special Article

Consensus on treatment of endometrium carcinoma with brachytherapy

Research Articles

Curcumin abrogates bile-induced NF-κB activity and DNA damage in vitro and suppresses NF-κB activity whilst promoting apoptosis in vivo, suggesting chemopreventative potential in Barrett’s oesophagus

Research Articles

Efficacy and safety of liposomal cytarabine in children with primary CNS tumours with leptomeningeal involvement

Educational Series/Red Series

Lynch syndrome diagnostics: decision-making process for germ-line testing
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits